Certolizumab Pegol

證據等級: L5

預測適應症: 6 個

Certolizumab Pegol: From Rheumatoid Arthritis to Rheumatoid Vasculitis

One-Sentence Summary

Certolizumab pegol (CZP, brand name Cimzia®) is a PEGylated anti-TNF-α biologic approved internationally for rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, and axial spondyloarthritis, though it has not been approved in Taiwan. The TxGNN model predicts it may be effective for Rheumatoid Vasculitis (score 99.78%), with 3 tangentially related clinical trials and 8 publications retrieved — however, the literature balance is striking: only 1 case report documents therapeutic benefit, while 4 case reports describe CZP-induced paradoxical vasculitis as an adverse drug reaction.

Quick Overview

Item	Content
Original Indication	Not registered in Taiwan; globally approved for Rheumatoid Arthritis, Crohn’s Disease, Psoriatic Arthritis, Axial Spondyloarthritis
Predicted New Indication	Rheumatoid Vasculitis
TxGNN Prediction Score	99.78%
Evidence Level	L4
Taiwan Market Status	✗ Not Marketed
Number of Taiwan Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Certolizumab pegol is an Fc-free, PEGylated antigen-binding fragment (Fab’) of a recombinant humanized monoclonal antibody that selectively neutralizes tumor necrosis factor-alpha (TNF-α). Unlike other anti-TNF biologics such as adalimumab or infliximab, CZP lacks the Fc region — a design that prevents complement-mediated cytotoxicity and significantly reduces placental transfer. Its efficacy in RA, Crohn’s disease, PsA, and axSpA is all grounded in blocking TNF-α-driven inflammatory cascades.

Rheumatoid vasculitis (RV) is a serious extra-articular complication of long-standing seropositive RA, in which systemic TNF-α-mediated inflammation extends to vessel walls, causing ischemic leg ulcers, mononeuritis multiplex, and organ ischemia. On mechanistic grounds, neutralizing TNF-α could theoretically suppress this vascular inflammation — the same mechanism that underpins CZP’s established efficacy in RA joint disease. This is the basis for the TxGNN model’s high prediction score.

However, the clinical signal is paradoxical and concerning. Four of the eight retrieved publications document vasculitis as an adverse drug reaction to CZP or other anti-TNF agents — including leukocytoclastic vasculitis, hypocomplementemic urticarial vasculitis (HUV), medium-vessel vasculitis, and rapidly progressive glomerulonephritis. The probable mechanism for these paradoxical reactions involves immune complex deposition and complement activation in the context of anti-TNF-induced autoimmunity. Only a single case report (PMID 34786446) documents CZP used therapeutically for RV-related leg ulcers with benefit. The current adverse safety signal substantially outweighs the single therapeutic data point, placing this prediction in “biologically plausible but clinically high-risk” territory.

Clinical Trial Evidence

No clinical trials directly evaluating CZP as a treatment for rheumatoid vasculitis were identified. The 3 retrieved trials have low direct relevance:

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07138898	Phase 2	Not Yet Recruiting	80	Compares two immunosuppressant hold strategies around elective shoulder arthroplasty in rheumatology patients; assesses flare incidence and wound complications — no vasculitis treatment focus
NCT05696106	N/A	Unknown	750,000	Large observational study evaluating the risk of developing additional IMIDs in patients already treated with biologics or immunosuppressants for a single IMID; provides general epidemiological background
NCT01579006	N/A	Completed	184	Observational study of tocilizumab (not CZP) in RA patients with inadequate response to DMARDs; evaluates clinical practice patterns over 6 months — minimal relevance

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36597972	2022	Cohort	RMD Open	Long-term follow-up of CZP in 80 patients with IMID-related uveitis; demonstrates effectiveness and acceptable safety of CZP across multiple immune-inflammatory conditions
36418084	2022	Review	RMD Open	Systematic comparison of infection type and frequency across immune-modulatory drugs using Summary of Product Characteristics data; establishes CZP’s infection safety profile in autoimmune disease treatment
34786446	2021	Case Report	JAAD Case Reports	Only therapeutic evidence: CZP successfully treated refractory leg ulcers due to rheumatoid vasculitis — sole case directly supporting this repurposing direction
41158918	2025	Case Report	Cureus	⚠️ Anti-TNF (certolizumab pegol)-induced medium-vessel vasculitis in a 33-year-old with seronegative RA after inadequate prior treatment responses — paradoxical adverse event
32687015	2021	Case Report	Modern Rheumatology Case Reports	⚠️ Rapidly progressive glomerulonephritis (pauci-immune, vasculitis-pattern) after introduction of CZP in a 30-year-old RA patient — autoimmune paradoxical reaction
31990069	2020	Case Report	J Clin Pharmacy & Therapeutics	⚠️ Hypocomplementemic urticarial vasculitis (HUV) developed during CZP treatment for RA — first reported case linking HUV specifically to CZP
29610119	2018	Retrospective Cohort	Clinical Medicine & Research	Single-center experience of cutaneous adverse events from biologic agents including CZP; documents a spectrum of skin and vascular reactions associated with anti-TNF use
28405087	2017	Case Report	Proceedings (Baylor Univ. Medical Center)	⚠️ Leukocytoclastic vasculitis as a drug reaction to CZP in a psoriatic arthritis patient — first reported case associating this reaction specifically with CZP among TNF antagonists

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Although TNF-α blockade is mechanistically plausible for rheumatoid vasculitis, the clinical evidence balance is unfavorable: 4 of 8 retrieved publications document vasculitis as a consequence of anti-TNF therapy rather than a treatable target, and only 1 case report supports therapeutic benefit. Proceeding without substantially more safety and efficacy data would expose patients to poorly characterized risk.

To proceed, the following is needed:

A structured retrospective case series or prospective registry documenting CZP use in confirmed rheumatoid vasculitis patients, with clear differentiation from drug-induced vasculitis
Mechanistic studies or biomarker work to distinguish patients who may benefit (TNF-driven RV) from those at risk of paradoxical worsening (anti-TNF-induced vasculitis)
Taiwan FDA package insert data for CZP: complete warning text, contraindications, and special population precautions
Drug-drug interaction (DDI) profile for CZP in the rheumatoid vasculitis treatment context (e.g., concurrent immunosuppressants such as cyclophosphamide, azathioprine)
Clarification of whether rheumatoid vasculitis patients were specifically included or excluded in the pivotal CZP RA clinical trials, and what outcomes were observed in that subset
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.